Several possible studies
Story checked
Imperial College London chemical engineer develops new technology to tackle global inequalities in vaccination coverage (opens in a new tab)
news-medical.net · 2026-09-16
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Imperial College London chemical engineer develops new technology to tackle global inequalities in vaccination coverage
news-medical.net · 2026-09-16
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedThe new technology could tackle global health inequalities by making vaccines easier to store, transport, and deploy without refrigeration.View evidenceHide evidence
As statedglobal health inequalities
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 4Not checkedApanpreet Kaur, a chemical engineer from Imperial College London, co-developed nanoparticles that keep vaccines stable in liquid form at room temperature.View evidenceHide evidence
As statedroom temperature; liquid form
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 4Not checkedThe article says many vaccines currently need refrigeration, which makes distribution to parts of developing nations difficult because of reliance on an expensive temperature-controlled transport and storage network.View evidenceHide evidence
As statedexpensive network
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 4Not checkedThe technology is undergoing a validation study with a world-leading pharmaceutical company, and the founders hope to start human trials within the next two years.View evidenceHide evidence
As statedwithin the next two years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Microneedles for Vaccination: Mechanistic Foundations, Materials Innovation, Clinical Translation, and Global Health Implementation.
Pharmaceutics · 2026 · PubMed
The thermostability of a Vaccine Delivery system X-Protein (VADEX-Pro) based protein nanoparticle
2023 · Crossref
Next-Generation Nanocarrier Platforms for RNA Vaccines: Advances in Formulation, Stability Engineering, and Translational Manufacturing Challenges.
2026 · Europe PMC
Expression and Characterization of SARS-CoV-2 RBD Recovered from Inclusion Bodies in E. coli by Using Mild Solubilization Method and Immunogenicity Improvement Thereof.
Indian Journal of Microbiology · 2026 · PubMed
Nickel nanoparticle-stabilized room-temperature blue-phase liquid crystals
Nanotechnology · 2018 · Crossref
And 10 more candidates considered.